Description
Generic
Indications
Olmesartan medoxomil is shown for the treatment of hypertension. It may be utilized alone or in combination with other antihypertensive specialists.
Pharmacology
Angiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). In-vitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).
Dosage & Administration
Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.
Interaction
With pharmaceutical: No critical medicate intuitive were detailed in which Olmesartan was co-administered.
With nourishment & others: Nourishment does not influence the bioavailability of Olmesartan.
Contraindications
Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.
Side Effects
Common: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and sinusitis.
Rare: Chest pain, peripheral edema, arthritis.
Pregnancy & Lactation
Pregnancy: When pregnancy is recognized, cease this item as before long as conceivable. When utilized in pregnancy amid the moment and third trimesters, drugs that act straightforwardly on the renin-angiotensin framework can cause harm and indeed passing to the creating fetus.
Nursing Moms: It isn’t known whether Olmesartan is excreted in human drain, but Olmesartan is discharged at low concentration within the drain of lactating rats. Since of the potential for unfavorable impacts on the nursing newborn child, a choice ought to be made whether to discontinue nursing or cease the medicate, taking into consideration the significance of the sedate to the mother.
Precautions & Warnings
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with olmesartan medoxomil.
Therapeutic Class
Angiotensin-ll receptor blocker
Storage Conditions
Protect from light and moisture by storing below 30°C. Keep the medicine out of children’s reach.
